VEGF concentration correlates to foveal thickness

Article

The concentration of vascular endothelial growth factor (VEGF) in the vitreous is associated with the mean thickness of the fovea as measured by optical coherence tomography (OCT), according to study results published online ahead of print by Investigative Ophthalmology & Visual Science.

The concentration of vascular endothelial growth factor (VEGF) in the vitreous is associated with the mean thickness of the fovea as measured by optical coherence tomography (OCT), according to study results published online ahead of print by Investigative Ophthalmology & Visual Science.

Hiroyuki Shimada of Nihon University, Tokyo, Japan and colleagues collected vitreous samples from the premacular vitreous and either the mid-vitreous (n=35, Group A) or the peripheral cortical vitreous (n=36, Group B) of diabetic macular oedema (DME) patients who had no posterior vitreous detachment and no previous panretinal photocoagulation. The team then used OCT to measure the mean foveal thickness and enzyme-linked immunosorbent assay to measure vitreous VEGF levels, and compared the results with those taken from the control group: eyes with stage 3 macular hole (n=10).

In the DME eyes, the mean concentration of VEGF in the premacular vitreous was 1386.2 pg/ml, with a standard deviation of 2134.1 pg/ml; in the peripheral cortical vitreous, the mean was 1169.7 pg/ml (SD=1840.3 pg/ml), and in the mid-vitreous, the mean concentration was 1080.9 pg/ml (SD=1534.1 pg/ml). In the control group, VEGF concentrations were below 20 pg/ml for each of the three measurement sites. The mean foveal thickness correlated to concentrations of VEGF at each of the areas of the vitreous tested.

The researchers concluded that, because of the correlation of foveal thickness and VEGF concentration, and the higher concentration of VEGF in the premacular vitreous when compared with the mid-vitreous and peripheral cortical vitreous, it is likely in DME eyes that VEGF is diffused from the macular to the periphery and from the posterior to the anterior globe.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.